Ekberg S, Smedby KE, Albertsson-Lindblad A, et al. Late Effects in Mantle Cell Lymphoma Patients Treated With or Without Autologous Stem Cell Transplantation. Blood Advances. 2022; (doi: 10.1182/bloodadvances.2022007241).
A study of the late effects of mantle cell lymphoma (MCL) found that most patients died from the disease, rather than as the result of another cause or treatment complication — highlighting the need for more efficient treatment options, according to the researchers. The population-based study involved 620 adult MCL patients diagnosed in 2000-2014 and included in the Swedish Lymphoma Register — 247 of whom received high-dose chemotherapy with autologous stem cell transplantation (HD-ASCT) — and 1:10 matched healthy controls. Using the national Patient Register and Cause-of-Death-Register, the patients and controls were tracked from one year post-diagnosis/matching until December 2017. MCL patients saw significantly higher rates of specialist and hospital visits compared with the control patients, and they also exhibited particularly high relative risks of infectious, respiratory, and blood disorders. Between HD-ASCT and non-HD-ASCT treated patients, there was no variation in complication rates, including secondary neoplasms, during this time frame.
Tags: study, patient care, Treatment, Cellular therapy, Mantle Cell, Lymphoma, Chemo, Cell Transplantation, cell therapy, researchers, Autologous, blood disorders, complication